Akebia to Present at the Oppenheimer 25th Annual Healthcare Conference

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the Oppenheimer 25th Annual Healthcare Conference on Thursday, December 11, 2014 at 1:00 p.m. Eastern Time. The conference will take place at Crowne Plaza Times Square Manhattan in New York City.

A live audio webcast of the presentations will be available on the company's website at http://ir.akebia.com/events.cfm. An archived presentation will be available for 90 days.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through HIF biology. Akebia's lead product candidate, AKB-6548, is a once-daily, oral therapy, which has completed a Phase 2b study for the treatment of anemia related to CKD in non-dialysis patients and is in a Phase 2 study for the treatment of anemia in patients undergoing dialysis. For more information on Akebia, please visit www.akebia.com.